Clinical Trials Logo

Seizures clinical trials

View clinical trials related to Seizures.

Filter by:

NCT ID: NCT03897985 Completed - Anesthesia Clinical Trials

Measurement of Anaesthesia-depth Trough Narcotrend TM in Patients Undergoing Electro-Convulsion-Therapy (ECT)- Influence of Anasthesia Depth on Quality of Convulsion

TM TradeMark
Start date: May 1, 2019
Phase:
Study type: Observational

The Electro-Convulsion-Therapy (ECT) is a well accepted treatment option in severe depression. The quality of ECT is evaluated basing on minimal seizure duration (>15sec), the sympathic response and the postictal EEG-suppression. For the treatment general anaesthesia is needed. On the other hand anaesthesia strongly influences the quality of the seizure. The goal is to find an anaesthesia-depth that is needed for the well-being of the patient and allows a good ECT. In daily routine the dose of anesthetic agents and the assesment of anesthesia-depth is based on the subjective estimation of the anesthetist and also on ealier interventions. The aim of the study is to assess any correlation between measured anesthesia-depth using the Narcotrend TM and the Quality of the ECT.

NCT ID: NCT03896386 Completed - Epilepsy Clinical Trials

EPIDOGS Digital Seizure Diary for Owners of Alerting Dogs

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

During a three-month period, the study subjects will be using an electronic diary app that they can download and install on their smartphones to register the occurrence of seizures and also to register the potential alerting behaviour of their dogs. This information will increase the knowledge of the accuracy of these alerts.

NCT ID: NCT03895658 Recruiting - Unipolar Depression Clinical Trials

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

Start date: June 26, 2024
Phase: Phase 1
Study type: Interventional

Background: Electroconvulsive therapy (ECT) is used to treat people with severe depression. During ECT, the brain is given electric pulses that cause a seizure. Although it is effective, it can cause side effects, including memory loss. Researchers want to study a new way to give ECT called iLAST. Objective: To see if iLAST is safe and feasible in treating depression. Eligibility: People ages 22 70 years old who have major depressive disorder and are eligible for ECT Design: Participants will be screened under protocol 01-M-0254. This includes: Medical and psychiatric history and exam Blood and urine tests Participants will be inpatients at the Clinical Center. They study has 3 phases and will last up to 20 weeks. Phase I will last 1 week. It includes: MRI: Participants will lie in a scanner that takes pictures of the body MEG: A cone over the participant s head will record brain activity. TMS: A wire coil placed on the participant s scalp will produce an electrical current to affect brain activity. SEP: An electrode on the participant s wrist will give a small electrical shock to test nerve function. Phase II will last 2 and a half weeks. It includes: Seven sessions of iLAST under general anesthesia. Participants may also get standard ECT. EEG: A small electrode placed on the participant s scalp will record brain waves. Interviews about mood, symptoms, and side effects. Participants facial expressions may be video recorded. TMS Phase III will last at least 1 week. It will include: MRI EEG TMS MEG Standard ECT if needed. Participants will have sessions every other day, 3 times a week. Sponsoring Institution: National Institute of Mental Health ...

NCT ID: NCT03892798 Completed - Clinical trials for Autism Spectrum Disorder

Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene

IRF2BPL
Start date: November 27, 2018
Phase:
Study type: Observational [Patient Registry]

This protocol serves as a data collection tool for individuals with variants (missense, nonsense, frameshifts) in the IRF2BPL gene (MIM 611720), which causes Neurodevelopmental Regression, Seizures, Autism and Developmental Delay (NEDAMSS, MIM 618088) and may be involved in other neurodevelopmental presentations. This information will be analyzed to develop a better understanding of the findings and progression of symptoms in individuals with variants in the IRF2BPL gene.

NCT ID: NCT03882671 Enrolling by invitation - Epilepsy Clinical Trials

Development of a Minimally Invasive Seizure Gauge

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The researchers are trying to assess changes in physiological signals before and during seizures.

NCT ID: NCT03860467 Completed - Epileptic Seizure Clinical Trials

Epileptic Seizures in Intensive Care Units

Start date: December 1, 2019
Phase:
Study type: Observational

This retrospective observational cohort study is to assess and analyze clinical, electroencephalographic, laboratory, comorbidity, and treatment characteristics of Intensive care unit (ICU)-patients with epileptic seizures and to subsequently compare their characteristics with ICU-patients with status epilepticus (SE).

NCT ID: NCT03856775 Completed - Clinical trials for Non-convulsive Seizures

Detecting Non-convulsive Seizures in the Paediatric Intensive Care Unit

Start date: August 1, 2019
Phase:
Study type: Observational

The objective of this study is to determine if paediatric intensive care nurses and physicians can identify non-convulsive seizures in critically ill children using quantitative electroencephalography (EEG), in real time at the bedside. Quantitative EEG is a computer software tool which summarizes large volumes of brain wave electrical activity, called EEG into simple graphs and patterns. This has helped to shorten the EEG reading time.The study will also describe the neurological outcome of children monitored this way and assess if it's possible to use this approach. The investigators hypothesis is that paediatric intensive care nurses and physicians with focused training should be the first to identify non-convulsive seizures at the bedside using quantitative EEG, with reasonable accuracy and reliability. They should be able to confirm their findings with a neurologist to treat seizures quickly without over treatment. Due to the small numbers in this pilot study, the investigators are unlikely to be able to draw definitive conclusions on the clinical effects of this approach on the short- or long-term outcomes. This proof-of-concept study should, enable the investigators to assess if it's possible to use this method for a future multi-centre controlled study.

NCT ID: NCT03848273 Recruiting - Stroke Clinical Trials

Post Stroke Epileptic Seizures Risk Forecast

POSTER-1
Start date: February 20, 2019
Phase:
Study type: Observational

Improve the effectiveness of treatment and prognosis in patients with cerebrovascular accident by early detection of the risk of developing epileptic seizures.

NCT ID: NCT03836924 Completed - Epilepsy Clinical Trials

A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

Start date: February 18, 2019
Phase:
Study type: Observational

The purpose of this study is to assess the safety of perampanel in the treatment of partial onset seizures in participants of age 12 years and older with epilepsy.

NCT ID: NCT03826056 Completed - Multiple Sclerosis Clinical Trials

Neurology Inpatient Clinical Education Trial

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

The objective of this study is to compare the effectiveness of a personalized patient education program to the current hospital education and evaluate its impact using patient satisfaction scores. The investigators hypothesize that a personalized patient education intervention will increase patient's understanding of their diagnosis and satisfaction with the care as reflected in the survey results.